Oxford Biomedica cuts 2026 revenue guidance by 17%

Oxford Biomedica has officially reduced its revenue guidance for 2026 by 17%. This downward revision of financial expectations has triggered a sharp decline in the company's stock price. Investors are reacting to the lowered projections, causing the stock to plunge as the market processes the updated fiscal outlook. The company's financial trajectory for the coming years has been adjusted, resulting in immediate negative pressure on its current market valuation and overall investor confidence.